Inhibikase Adds Drug Development Veteran to Board Amid Phase 3 Trial
WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) appointed veteran pharmaceutical executive Scott M. Wasserman to its board of directors, effective October 19, as the company advances a global Phase …
Inhibikase Adds Drug Development Veteran to Board Amid Phase 3 Trial Read More